Trabectedin Continuation vs. Interruption in Soft-Tissue Sarcoma
the Cancer Therapy Advisor take:
According to a new study published in the journal The Lancet Oncology, researchers have found that it is better to continue trabectedin treatment until disease progression rather than discontinue therapy after six treatment cycles in patients with advanced, doxorubicin-refractory soft-tissue sarcoma.
For the open-label, non-comparative, multicenter, phase II study, researchers administered trabectedin 1.5mg/m2 as a continuous 24-hour IV infusion every 3 weeks to patients with advanced soft-tissue sarcomas who had previously received doxorubicin-based chemotherapy.
After six treatment cycles, patients free from disease progression were randomly assigned to continue treatment or discontinue treatment. Of 178 enrolled, 91 had not progressed after six cycles, and 53 were randomly assigned to either of the groups.
Results showed that the 6-month progression-free survival was 51.9% (95% CI: 31.9 - 68.6) and 23.1% (9.4 - 40.3) in the continuation group and interruption group, respectively (P = 0.0200). The frequency of adverse events was similar in both groups.
The authors conclude that trabectedin discontinuation should not be recommended in those who have not progressed after six treatment cycles.
Researchers have found that it is better to continue trabectedin treatment until disease progression rather than discontinue therapy.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- A Vegan Diet and Cancer
- As HPV-Related Cancer Rates Climb, Experts Scrutinize Barriers to HPV Vaccination
- Bowel Preparation for Colorectal Cancer Screening: Improving Outcomes
- Tool for Assessing Frailty Predicts Survival in Newly Diagnosed Multiple Myeloma
- Analysis Supports Flat Dose of Nivolumab 480 mg Every 4 Weeks
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Prostate Cancer Drug Treatments
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Treatment Delays May Mean Worse Survival in Head and Neck Cancer
- New Combo for Chronic Myeloid Leukemia Shows Activity In Vitro
- Age-adjusted Comorbidity Predicts Survival in Laryngeal Cancer
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Role of miR-125a-5p Clarified in Bladder Cancer